Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients
PROTEOMICS · 2025
DOI: 10.1002/pmic.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, 2025. Verfasst von Ivo Fabrik und 12 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. Hauptthemen laut MEDLINE: Memantine, Alzheimer Disease, Hippocampus, Glutamic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grantová Agentura České Republiky, Ministerstvo Zdravotnictví Ceské Republiky, Univerzita Karlova v Praze.
Themen: Demenz
Abstract (Originalsprache)
One of the traditional treatments in Alzheimer's disease (AD) is administration of memantine, the NMDA receptor antagonist. However, the molecular mechanism of the complex memantine action and the impact on the hippocampal proteome in humans is unknown. In this study, hippocampal proteins extracted from formalin‐fixed paraffin‐embedded post mortem tissues obtained from healthy donors ( n = 15), AD patients not treated with memantine ( n = 11), and AD patients treated with memantine ( n = 8) were investigated using tandem mass tag (TMT)‐based quantitative proteomics. Memantine medication induced subtle but distinct changes in the hippocampal proteome in AD patients. Although it did not prevent the metabolic and physiologic decline associated with AD pathology, memantine administration upregulated several mitochondrially encoded proteins and mitigated the proteomic pattern of activated phagocytes. Furthermore, memantine specifically enhanced the expression of postsynaptic glutamatergic and GABAergic receptors and components of the respective pathways without affecting presynaptic proteome. This suggests that memantine treatment in AD patients not only alleviates excitotoxic stress by inhibiting NMDA receptor activity, but also triggers broader adaptations in the synaptic signaling and plasticity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
- National Institute of Mental Health, Klecany, Czech Republic.
- Third Faculty of Medicine, Charles University Ruska 87, Prague, Czech Republic.
- Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
- The Fingerland Department of Pathology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
- Department of Pathology, Military University Hospital Prague, Prague, Czech Republic.
ORCID-Profile: Ondrej Soukup
Förderung
- Grantová Agentura České Republiky
- Ministerstvo Zdravotnictví Ceské Republiky
- Univerzita Karlova v Praze
- Ministerstvo Školství, Mládeže a Tělovýchovy
Zitieren
APA
Fabrik, I., Kupcik, R., Fabrikova, D., Chvojkova, M., Holubova, K., Hakenova, K., Horak, M., Soukup, J., Manethova, M., Rusina, R., Matej, R., Ryska, A., & Soukup, O. (2025). Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients. PROTEOMICS. https://doi.org/10.1002/pmic.70006
Vancouver
Fabrik I, Kupcik R, Fabrikova D, Chvojkova M, Holubova K, Hakenova K, et al. Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients. PROTEOMICS. 2025. doi:10.1002/pmic.70006
BibTeX
@article{Fabrik2025,
author = {Fabrik, Ivo and Kupcik, Rudolf and Fabrikova, Daniela and Chvojkova, Marketa and Holubova, Kristina and Hakenova, Kristina and Horak, Martin and Soukup, Jiri and Manethova, Monika and Rusina, Robert and Matej, Radoslav and Ryska, Ales and Soukup, Ondrej},
title = {Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients},
journal = {PROTEOMICS},
year = {2025},
doi = {10.1002/pmic.70006}
}
EUVIMED